Abstract：
Blueberries and cranberries are berry fruits with the highest number of randomized clinical trials (RCTs) focusing on blood pressure (BP). This systematic review and meta-analysis of RCTs analyzed the effects of blueberry and cranberry supplementation alone and in concert with systolic BP (SBP) and diastolic BP (DBP) in patients with cardiometabolic diseases. The searches were performed until August 2023 in the following databases: PubMed, Scopus, Web of Science, Cochrane, and Embase. Studies that examined the effects of blueberry or cranberry intake/supplementation were included. The risk of bias was evaluated using the Rob 2 scale. A meta-analysis was performed to estimate the effects of blueberry and cranberry supplementation on BP levels in patients with cardiometabolic diseases. A total of 17 articles were included, from which two found significant results from blueberry and/or cranberry supplementation in reducing BP. Pooled results revealed statistically non-significant reductions of -0.81 mm Hg for SBP (95% confidence interval [CI]: -2.26, 0.63; I2 = 0%) and -0.15 mm Hg for DBP (95% CI: -1.36, 1.05; I2 = 27%). Blueberry and/or cranberry supplementation had neutral effects on SBP and DBP in patients with cardiometabolic diseases, regardless of duration or age. Further high-quality studies are needed to firmly establish clinical efficacy.
摘要：
蓝莓和蔓越莓是浆果水果，其随机临床试验（RCT）的数量最多，关注血压（BP）。这项对RCT的系统评价和荟萃分析分析了心脏代谢疾病患者单独补充蓝莓和蔓越莓以及与收缩压（SBP）和舒张压（DBP）相一致的效果。搜索一直持续到2023年8月，在以下数据库中进行：PubMed，Scopus,WebofScience,科克伦,和Embase。包括检查蓝莓或蔓越莓摄入/补充的影响的研究。使用Rob2量表评估偏倚风险。进行了荟萃分析，以评估蓝莓和蔓越莓补充剂对心脏代谢疾病患者BP水平的影响。共收录17篇文章,其中两个发现了补充蓝莓和/或蔓越莓在降低血压方面的显著结果。汇总结果显示，SBP的-0.81mmHg（95％置信区间[CI]：-2.26，0.63；I2=0％）和DBP的-0.15mmHg（95％CI：-1.36，1.05；I2=27％）在统计学上没有显着降低。蓝莓和/或蔓越莓补充剂对心脏代谢疾病患者的SBP和DBP具有中性作用，无论时间长短或年龄。需要进一步的高质量研究来确定临床疗效。
